Company / R&D Expense
DarioHealth Corp. R&D Expense History
FY2014-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.3M
FY2018
5-year range
$2.2M / $4.9M
FY2014-FY2018
Trend
+53.1%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2018 after 3 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2018 with a 3-year CAGR of -5.8%.
Improved from $3M to $3M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -5.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -5.8%, indicating a declining trend.
- In FY2018, r&d expense increased 53.1% year-over-year.
- Peak r&d expense was recorded in FY2014.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -2.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $3.3M | +53.1% |
| FY2017 | $2.2M | -16.0% |
| FY2016 | $2.6M | -34.9% |
| FY2015 | $3.9M | -19.7% |
| FY2014 | $4.9M | - |
As of FY2018 · SEC 10-K Annual Filings · Updated Jun 24, 2026